Market Trends of Global Attention Deficit Hyperactivity Disorder Industry
This section covers the major market trends shaping the Attention Deficit Hyperactivity Disorder Market according to our research experts:
Stimulant Drug Type Segment is Expected to Projected Significant Growth Over the Forecast Period.
The stimulant segment dominated the ADHD market and is expected to continue to do so throughout the forecast period. This is due to the high demand for these drugs, which stems from their efficacy in treating symptoms of attention deficit hyperactivity disorder, ongoing clinical trials, and government support for the use of stimulants in the treatment of mental health disorders. Stimulant drugs include Amphetamine, Methylphenidate, Lisdexamfetamine, and Dexmethylphenidate.
Amphetamines (e.g., Adderall) and methylphenidate (e.g., Ritalin and Concerta) are common stimulant medications prescribed to children, adolescents, and adults with attention deficit hyperactivity disorder (ADHD). The study titled "A cognitive neuroscience review of the etiology of ADHD," published by the Association of Child and Adolescent Mental Health in January 2022, describe that stimulant works quickly, and there is also a reduction in overall impulsivity and ADHD symptoms in two hours. It also reported that stimulants are the most effective treatment for ADHD patients to keep them calm and focused. Thus the effectiveness of the stimulant drug in the management of ADHD boosts the segment growth over the forecast period.
Furthermore, a rise in clinical studies to evaluate the effectiveness of the stimulant drug in ADHD treatment is anticipated to drive the segment over the forecast period. For instance, as per the ClinicalTrial.gov updates on July 2021, the study titled "A Pivotal Efficacy Trial to Evaluate HLD200 (methylphenidate) in Children With ADHD in a Classroom Setting" under the development phase III by Ironshore Pharmaceuticals and Development, Inc. Hence, the increase in the number of drug development will be expected to increase in the accessibility of ADHD therapeutics and thus anticipated to boost the segment growth.
Moreover, the approval and commercialization of new drugs by market players are also expected to play a crucial role in driving market growth over the coming years. For instance, in March 2021, Azstarys (KemPharma) received Food and Drug Administration approval for a central nervous system stimulant for the treatment of ADHD. It is one of the first drugs with the combination of dexmethylphenidate and serdexmethylphenidate. Such approvals are propelling the growth of the market segment.
Thus, the aforementioned factors are likely to drive the growth of the segment during the forecast period.
North America Holds a Significant Share in the Market and Do the Same during the Forecast Period
North America dominates the ADHD market over the forecast period. This is due to the large number of drug prescriptions written each year, the increased number of product launches, and the increased collaboration among players to improve market penetration and product development.
Furthermore, rising in the prevalence of ADHD in the country is anticipated to drive the market over the forecast period. According to the Centers for Diseases Control and Prevention, in September 2021, 8.8% of people have been diagnosed with ADHD at some point in their lives. Moreover, 13.6 million visits to doctors' offices were made with attention deficit disorder as the primary diagnosis.
In addition, increasing spending on the treatment of ADHD in the United States with rising prescription rates is expected to boost the market. According to the study titled "Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective," published in the Managed Care and Specialty Pharmacy in February 2022, in the United States, an estimated 8,716,972 adults have ADHD, resulting in a total societal excess cost of USD 122.8 billion (USD 14,092 per adult). Thus rise in healthcare spending is anticipated to drive the market growth over the forecast period.
Additionally, approval and commercialization of new drugs are also expected to play a key role in driving market growth in the coming years. For instance, in April 2021, the Food and Drug Administration approved Qelbree (KELL'-bree for treating attention deficit hyperactivity disorder in children ages 6 to 17.
Furthermore, in February 2021, Noven Pharmaceuticals Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) seeking approval to market its dextroamphetamine transdermal system for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) for patients six years and older.
Thus, the aforementioned factors are likely to drive the growth of the marker during the forecast period.
